Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables: 2023-2024

Historic Receivables for BridgeBio Pharma (BBIO) over the last 2 years, with Dec 2024 value amounting to $4.7 million.

  • BridgeBio Pharma's Receivables was N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $313.4 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 100.85% up from last year.
  • As of FY2024, BridgeBio Pharma's Receivables stood at $4.7 million, which was up 100.85% from $2.4 million recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Receivables ranged from a high of $4.7 million in FY2024 and a low of $2.4 million during FY2023.
  • For the 2-year period, BridgeBio Pharma's Receivables averaged around $3.5 million, with its median value being $3.5 million (2023).
  • Data for BridgeBio Pharma's Receivables shows a peak YoY soared of 100.85% (in 2024) over the last 5 years.
  • BridgeBio Pharma's Receivables (Yearly) stood at $2.4 million in 2023, then skyrocketed by 100.85% to $4.7 million in 2024.